The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mm content recommended for you
Should all patients with MM receive maintenance therapy after transplantation?
Featured:
Graham JacksonDuring the 6th World Congress on Controversies in Multiple Myeloma (COMy) the Multiple Myeloma Hub spoke to Graham Jackson, Newcastle University, Newcastle upon Tyne, UK, about maintenance therapy after transplantation. We asked, Should all patients with MM receive maintenance therapy after transplantation?
Should all patients with MM receive maintenance therapy after transplantation?
Graham Jackson explains that we have a lot of evidence suggesting that maintenance therapy has an impact on progression-free survival (PFS) and overall survival (OS) in patients with MM. In particular, results from different studies show that lenalidomide (Revlimid®) maintenance, compared with placebo or no maintenance, significantly improves PFS and OS. In addition to lenalidomide, maintenance therapy with other agents, such as bortezomib (Velcade®) and ixazomib, significantly improves the outcomes of patients with MM. He concludes that, even though a lot of questions are still unanswered, maintenance therapy is important for all patients with MM after transplantation.